Do you want to read an article? Please log in or register.
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma
Skin Cancer
Related content
Skin Cancer
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients
Eur J Cancer
Robert C, Long GV, Larkin J, Wolchok JD, Hassel JC, Schadendorf D, Hodi FS, Lebbé C, Grob JJ, Hyngstrom JR, Wagstaff J, Chesney J, Butler MO, Bechter O, Márquez-Rodas I, Pavlick AC, Durani P, Pe Benito M, Wang P, Postow MA, Ascierto PA
doi: 10.1016/j.ejca.2024.115119
ESMO 2024
Skin Cancer
CheckMate 067: Sustained survival benefit with nivolumab plus ipilimumab and nivolumab monotherapy versus ipilimumab in patients with advanced melanoma
Skin Cancer
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
N Engl J Med
Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, Queirolo P, Dummer R, Butler MO, Hill AG, Postow MA, Gaudy-Marqueste C, Medina T, Lao CD, Walker J, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Sandhu S, Lebbé C, Ascierto PA, Long GV, Ritchings C, Nassar A, Askelson M, Benito MP, Wang W, Hodi FS, Larkin J, CheckMate 067 Investigators
doi: 10.1056/NEJMoa2407417
Skin Cancer
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma
Eur J Cancer
Handel EE, McKeown J, Wei J, Kankaria RA, Burnette H, Johnson DB, Lawless A, Czapla J, Sullivan RJ, Albrecht LJ, Zimmer L, Mangana J, Dummer R, Kessels JI, Neyns B, Allayous C, Lebbe C, Boatwright C, Mehnert JM, Ottaviano M, Ascierto PA, Czarnecka AM, Rutkowski P, Lo SN, Long GV, Menzies AM, Carlino MS
doi: 10.1016/j.ejca.2024.115171
Skin Cancer
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
J Clin Oncol
Long GV, Lipson EJ, Hodi FS, Ascierto PA, Larkin J, Lao C, Grob JJ, Ejzykowicz F, Moshyk A, Garcia-Horton V, Zhou ZY, Xin Y, Palaia J, McDonald L, Keidel S, Salvatore A, Patel D, Sakkal LA, Tawbi H, Schadendorf D
doi: 10.1200/JCO.24.01125
ASCO 2024
Skin Cancer
COMBI-AD: Long-term outcomes favor dabrafenib plus trametinib versus placebo in patients with BRAF-mutated stage III melanoma
ELCC 2024
Lung, Respiratory and Thoracic Cancer
FLAURA2: Osimertinib plus chemotherapy provides long-term benefits in post-progression outcomes versus osimertinib alone in EGFR-mutated advanced NSCLC
Skin Cancer
Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study
Eur J Cancer
Schadendorf D, Lord-Bessen J, Ejzykowicz F, Shi L, Yu P, Srinivasan S
doi: 10.1016/j.ejca.2024.115099
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Long term outcomes after lobar versus sublobar resection for patients with Non-Small cell lung Cancer: Systematic review and individual patient data Meta-Analysis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Tasoudis P, Loufopoulos G, Manaki V, Doerr M, Agala CB, Long JM, Haithcock BE
doi: 10.1016/j.lungcan.2024.107929